Abstract
Cyclosporine A (CsA) is an immunomodulator that inhibits T-cell mediated immunoreactivity.1–4 In addition, data indicate that CsA may act as an anti-inflammatory, due to its phosphatase inhibition activity. Because of these actions, CsA ophthalmic emulsion formulation was developed by Allergan for treatment of keratoconjunctivitis sicca. Since the safety profile of this new formulation is very important for the clinical success of the drug, long-term safety studies were carried out as described below.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effect of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976; 6: 468–475.
Bord JF. Cyclosporine: historical perspectives. Transplant Proc. 1983; 15: 3–13.
Shevach EM. The effects of cyclosporine A on the immune system. Annu Rev Immunol. 1985; 3: 397–423.
Kahan BD, Bach JF (eds). Proceedings of the Second International Congress on Cyclosporine. Transplant Proc. 1988;20, Suppl. 3: 1–1131.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Angelov, O., Wiese, A., Yuan, Y., Andersen, J., Acheampong, A., Brar, B. (1998). Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion. In: Sullivan, D.A., Dartt, D.A., Meneray, M.A. (eds) Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2. Advances in Experimental Medicine and Biology, vol 438. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5359-5_142
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5359-5_142
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7445-9
Online ISBN: 978-1-4615-5359-5
eBook Packages: Springer Book Archive